Details for Patent: 9,649,284

Which drugs does patent 9,649,284 protect, and when does it expire?

Patent 9,649,284 protects CALDOLOR and is included in one NDA.

This patent has twenty-three patent family members in nine countries.

Summary for Patent: 9,649,284

Title:	Treating critically ill patients with intravenous ibuprofen
Abstract:	Methods of treating at least one condition chosen from pain, inflammation, and fever in a critically ill patient in need thereof, comprising administering to the critically ill patient an intravenous pharmaceutical composition comprising ibuprofen using a first dosage regimen, wherein the first dosage regimen produces a first pharmacokinetic profile in critically ill patients that is about equivalent to a second pharmacokinetic profile produced by administration of the intravenous pharmaceutical composition using a second dosage regimen of ibuprofen to non-critically ill patients, wherein the at least one condition of the critically ill patient is thereby treated.
Inventor(s):	Pavliv; Leo (Cary, NC), Rock; Amy Dix (Nashville, TN)
Assignee:	Cumberland Pharmaceuticals, Inc. (Nashville, TN)
Application Number:	14/825,803
Patent Claim Types: see list of patent claims	Use; Composition;

Drugs Protected by US Patent 9,649,284

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Cumberland Pharms	CALDOLOR	ibuprofen	SOLUTION;INTRAVENOUS	022348-002	Jun 11, 2009		RX	Yes	Yes						MANAGEMENT OF MILD TO MODERATE PAIN, MANAGEMENT OF MODERATE TO SEVERE PAIN AS AN ADJUNCT TO OPIOID ANALGESICS IN A CRITICALLY ILL PATIENT WITH INTRAVENOUS IBUPROFEN IN NEED THEREOF

International Family Members for US Patent 9,649,284

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2009350474
Australia	2010274030
Brazil	112012000773
Brazil	PI0925034
Canada	2766367
Canada	2767971
Canada	2785360